Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
WINT | US
0.16
17.16%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.07
1.05
1.20
1.02
Windtree Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF an aerosolized KL4 surfactant which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin a lyophilized KL4 surfactant which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator which is in preclinical trial for the treatment of chronic and acute heart failure. Windtree Therapeutics Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve S.A. for the development marketing and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories Inc. and changed its name to Windtree Therapeutics Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington Pennsylvania.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
269.7%1 month
245.3%3 months
396.5%6 months
2133.1%-
0.37
1.04
0.37
0.13
0.01
706.08
-
-24.66M
3.94M
3.94M
-
-
-
-100.00
-150.80
0.07
6.13
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.54
Range1M
2.80
Range3M
14.09
Rel. volume
6.29
Price X volume
19.49M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
AquaBounty Technologies Inc | AQB | Biotechnology | 1.1 | 4.25M | -8.33% | n/a | 10.41% |
Titan Pharmaceuticals Inc | TTNP | Biotechnology | 4.58 | 4.19M | -4.38% | n/a | 0.00% |
NuCana plc | NCNA | Biotechnology | 1.86 | 4.18M | -1.06% | n/a | 0.00% |
Fresh America Corp | FRES | Biotechnology | 1.66 | 4.07M | -15.74% | n/a | 0.22% |
Lipella Pharmaceuticals Inc. Common Stock | LIPO | Biotechnology | 0.4896 | 3.97M | -0.99% | n/a | 5.50% |
Genprex Inc | GNPX | Biotechnology | 1.51 | 3.91M | 265.62% | n/a | 0.00% |
InMed Pharmaceuticals Inc | INM | Biotechnology | 0.29 | 3.87M | 21.04% | n/a | 7.00% |
Neurotrope Inc | NTRP | Biotechnology | 2.4 | 3.80M | 0.00% | n/a | 0.00% |
Gritstone Oncology Inc - Ordinary Shares | GRTS | Biotechnology | 0.0322 | 3.80M | -31.78% | n/a | 461.91% |
Sonnet BioTherapeutics Holdings Inc | SONN | Biotechnology | 5.71 | 3.71M | -3.38% | n/a | 5.74% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.01 | 0.53 | Cheaper |
Ent. to Revenue | 706.08 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 1.04 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 396.51 | 72.80 | Riskier |
Debt to Equity | 0.37 | -1.23 | Expensive |
Debt to Assets | 0.13 | 0.25 | Cheaper |
Market Cap | 3.94M | 3.66B | Emerging |